These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21921645)

  • 41. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M; Mueller BA; Segal JH
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
    Yu JM; Shord SS; Cuellar S
    J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
    Borg S; Glenngård AH; Osterborg A; Persson U
    Acta Oncol; 2008; 47(6):1009-17. PubMed ID: 18770060
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
    Costiniuk CT; Camacho F; Cooper CL
    Clin Infect Dis; 2008 Jul; 47(2):198-202. PubMed ID: 18532889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy.
    Hedenus M; Näsman P; Liwing J
    J Clin Pharm Ther; 2008 Aug; 33(4):365-74. PubMed ID: 18613854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy.
    Lalle M; Pistillucci G; Antimi M; D'Aprile M
    J Exp Clin Cancer Res; 2005 Jun; 24(2):197-201. PubMed ID: 16110751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correcting iron-restricted erythropoiesis and improving anemia in patients on hemodialysis: practical tips that can make a difference.
    Easom A
    Nephrol Nurs J; 2009; 36(5):529-37, 553. PubMed ID: 19856814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?
    Shander A; Spence RK; Auerbach M
    Transfusion; 2010 Mar; 50(3):719-32. PubMed ID: 19919555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reassessments of ESAs for cancer treatment in the US and Europe.
    Bennett CL; McKoy JM; Henke M; Silver SM; MacDougall IC; Birgegård G; Luminari S; Casadevall N; Schellekens H; Sartor O; Lai SY; Armitage JO
    Oncology (Williston Park); 2010 Mar; 24(3):260-8. PubMed ID: 20394138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.
    Ludwig H; Aapro M; Bokemeyer C; Macdonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
    Eur J Cancer; 2009 Jun; 45(9):1603-15. PubMed ID: 19278851
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy.
    Rodgers GM; Gilreath JA
    Acta Haematol; 2019; 142(1):13-20. PubMed ID: 30970366
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Iron deficiency and anemia in oncology].
    Scotté F; Launay-Vacher V; Ray-Coquard I
    Bull Cancer; 2012 May; 99(5):563-70. PubMed ID: 22516641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of intravenous iron in cancer-related anemia.
    Henry DH
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):21-4. PubMed ID: 16925107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The addition of oral iron improves chemotherapy-induced anemia in patients receiving erythropoiesis-stimulating agents.
    Tan J; Du S; Zang X; Ding K; Ginzburg Y; Chen H
    Int J Cancer; 2022 Nov; 151(9):1555-1564. PubMed ID: 35639027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of anemia in patients with solid tumors receiving chemotherapy in palliative setting: usual practice versus guidelines.
    de Putter R; Geboes K; De Man M; Van Belle S
    Acta Clin Belg; 2018 Aug; 73(4):251-256. PubMed ID: 29336240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing Chemotherapy-Induced Anemia with Erythropoiesis-Stimulating Agents Plus Iron.
    Whitehead L
    Am J Nurs; 2017 May; 117(5):67. PubMed ID: 28448368
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials.
    Gafter-Gvili A; Rozen-Zvi B; Vidal L; Leibovici L; Vansteenkiste J; Gafter U; Shpilberg O
    Acta Oncol; 2013 Jan; 52(1):18-29. PubMed ID: 22877242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Update on safety of ESAs in cancer-induced anemia.
    Glaspy J
    J Natl Compr Canc Netw; 2012 May; 10(5):659-66. PubMed ID: 22570294
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.
    Hörbrand F; Rottenkolber D; Fischaleck J; Hasford J
    Gesundheitswesen; 2014 Nov; 76(11):e79-84. PubMed ID: 24493578
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.
    Del Vecchio L; Locatelli F
    Expert Rev Hematol; 2014 Aug; 7(4):495-506. PubMed ID: 25025373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.